The Opportunity
ABV100 platform will become a replacement for rapid acting insulin that can be used anywhere and with any patient type (T1D, T2D, Injections, pumps)
Protects against hypoglycemia allowing safer use of insulin and better control of diabetes that in turn allows much improved long term health
Pharmacological platform leverages two well known FDA-approved peptides (many decades of use in humans)
Human proof of concept already achieved with prototype co-formulations
- De-risked and streamlined path to market
- Non-dilutive funding, strong IP position
Milestones
- Proof of concept in a large animal model
- Human POC study using a co-infusion has validated the approach
- Candidate formulations demonstrate feasibility of a stable combination product
- Strong IP Portfolio
- Non-dilutive funding to date